AMAR - Amarillo Biosciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0000 (0.00%)
At close: 2:52PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
Previous Close0.2350
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2350 - 0.2350
52 Week Range0.1840 - 0.4700
Avg. Volume3,013
Market Cap9.521M
Beta (5Y Monthly)-0.19
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
Press Releases
  • GlobeNewswire

    Amarillo Biosciences to Explore Low-Dose Oral Interferon Therapeutics in China as a Line of Defense Against Coronavirus and Other Viral Indications

    Amarillo, TX, Feb. 13, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarillo Biosciences, Inc. (“ABI” or the “Company”), (AMAR), a diversified healthcare company, today announced that its China licensing partner, Xiamen Weiyang Pharmaceutical Co., Ltd. (“Xiamen Weiyang”), has begun initiating the sharing of proprietary clinical research information with health officials in China to potentially explore the effect of ABI’s low-dose oral interferon in combating the spread of novel coronavirus, now officially known as Covid-19, along with other related viral indications such as influenza. There are currently no approved therapeutics or vaccines for Covid-19.

  • GlobeNewswire

    Amarillo Biosciences and Xiamen Weiyang Pharmaceutical Sign Term Sheet Outlining China Licensing and Royalty Agreement

    Amarillo, TX, July 29, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarillo Biosciences, Inc. (“ABI” or the “Company”), (AMAR), a diversified healthcare company, today announced that it has entered into a Term Sheet outlining a licensing and royalty agreement with Xiamen Weiyang Pharmaceutical Co., Ltd., a company organized under the laws of the People’s Republic of China (“Xiamen Weiyang”), setting forth the proposed terms for a cooperative development and licensing venture in China.  The consummation of the proposed transaction is contingent on a mutually agreeable definitive agreement. Dr. Stephen T. Chen, ABI’s CEO, stated, “We are pleased to announce this proposed venture with Xiamen Weiyang.